CME Outfitters announces an upcoming live and interactive neuroscienceCME TV activity titled "Augmenting Antidepressants with Atypical Antipsychotics in Major Depressive Disorder." Offered as a simultaneous satellite broadcast, webcast, and telephone audioconference premiering Wednesday, June 11, 2008, from 12:00 p.m.-1:00 p.m.
Palatin Technologies has initiated dosing in a Phase 2a clinical study of PL-3994, a novel, long-acting natriuretic peptide receptor A agonist, in subjects with controlled hypertension.
Patients with Lennox-Gastaut syndrome treated with the investigational antiepileptic agent rufinamide as adjunctive therapy experienced more than 40% fewer drop attacks than patients who received placebo.
Covalon Technologies has signed a development agreement for the application of its proprietary antimicrobial coating on percutaneous urinary catheters.
Almac Clinical Technologies has signed $12 million worth of new studies within the past several weeks, including one of the largest studies in the company's history.
Spear Pharmaceuticals has received the FDA approval for, and began shipping, Fluorouracil cream 5%, USP, a generic equivalent to Valeant's Efudex cream.
Schering-Plough has announced that it is initiating two large Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, in patients chronically infected with hepatitis C virus genotype 1.
Medarex has announced positive safety data from two Phase I trials that support the Phase II clinical development program of MDX-1100, a fully human monoclonal antibody that targets CXCL10, for the treatment of inflammatory diseases.
Morphotek, a subsidiary of Eisai, has signed a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, for the development of human monoclonal antibodies for the treatment
Amsterdam Molecular Therapeutics has announced that it obtained a license from La Sapienza University in Rome, Italy, to their advanced small nuclear RNA-based exon-skipping technology for the treatment of Duchenne muscular dystrophy.
GenVec has received a grant from the National Eye Institute, of the National Institutes of Health, to explore mechanisms regulating pigment epithelium-derived factor, a key regulator of blood vessel growth in the eye.
Lumedx, a provider of cardiovascular imaging and information systems, has introduced new software to manage data and track patients on long-term Coumadin therapy.
ImmunoCellular Therapeutics has announced that recently completed proof-of-principle studies demonstrate efficacy of its cancer stem cell vaccine technology in treating glioblastoma, a form of brain cancer, in preclinical animal models.
NeoPharm has enrolled its first patient in its Phase I clinical trial for LE-DT, a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere, which is used for the treatment of patients with metastatic solid cancer.
Barc has signed a broad biobanking agreement to support HIV vaccine trials currently being performed in South Africa by the HIV Vaccine Trials Network.
Pfizer has announced that Lipitor 80mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 27% in patients with heart disease who had previous coronary bypass surgery compared with patients taking the 10mg dose of
